ARTICLE | Politics & Policy
FTC to change reporting rules for biotech license deals
August 18, 2012 12:11 AM UTC
The U.S. Federal Trade Commission (FTC) is seeking comments on a proposed rule that would require biotech and pharma companies to report all "commercially significant" patent licensing deals to the FTC and Department of Justice for antitrust review. According to an FTC spokesperson, the change would be a "significant" revision to reporting requirements and lead to an estimated 30 additional filings per year. ...